New report published by Global Info Research which offers insights on the global Humira market.
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Click to view the full report TOC, figure and tables:
Global Humira Market: Forecast by Type / Application / Region
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis.
The major players in global Humira market include: AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim.
On the basis of product, the Humira market is primarily split into: Humira Syringe, Humira Pen.
On the basis on the end users/applications covers： Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and Other.
In the last several years, global market of Humira developed rapidly, with an average growth rate of 14.82%. In 2017, global revenue of Humira is nearly 18.92 Billion USD; the actual sales is about 8.99 million units. Humira’s U.S. patent expired in 2016, Amgen will Launch of Humira Biosimilar Amjevita 2018 in Europe and 2023 in American. Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira, for the treatment of multiple chronic inflammatory diseases in 2017. And In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe in 2017 is about 78%, and the proportion is in decreasing trend from 2013 to 2017.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion in 2017 is about 43%, and the proportion is in decreasing trend from 2013 to 2017.
Ask for Discount on Research Report and Request Sample Copy of Report@
GlobalInfoResearch is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.
United States Humira Market 2018 Forecast to 2023
Europe Humira Market 2018 Forecast to 2023
North America Humira Market 2018 Forecast to 2023
Asia-Pacific Humira Market 2018 Forecast to 2023
China Humira Market 2018 Forecast to 2023
EMEA Humira Market 2018 Forecast to 2023
Global Humira Market 2018 Forecast to 2023
Contact US :
Sales Director (Global Info Research)
Tel: +86-13660489451 00852-58197708(HK)
Add: RM 1605C HO KING COMM CTR 2-16 FA YUEN ST MONGKOK KL Hong Kong